Investors in Disc Medicine, Inc. (IRON) Warned of Potential Securities Fraud

Contact Levi & Korsinsky Today

Apr. 6, 2026 at 4:42am

Got story updates? Submit your updates here. ›

Levi & Korsinsky has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) concerning potential violations of federal securities laws. The investigation focuses on whether the company and its executives made statements to investors about the regulatory prospects of its lead drug candidate bitopertin that did not fully reflect the risks and challenges encountered in interactions with the FDA prior to the agency issuing a Complete Response Letter.

Why it matters

Disc Medicine's bitopertin was positioned as a potentially transformative therapy for the approximately 4,000 EPP patients in the United States, and the FDA's Complete Response Letter effectively delays any potential approval until at least 2027, eliminating the near-term commercial revenue that analysts had incorporated into their valuation models. The severity of the stock decline reflects the market's high expectations based on the company's prior public communications.

The details

On February 13, 2026, Disc Medicine disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL indicates that the FDA has completed its review of a drug application and determined that it cannot approve the application in its current form, requiring additional data submissions before the agency will reconsider the application.

  • On February 13, 2026, Disc Medicine disclosed the FDA's Complete Response Letter for bitopertin.
  • Following the CRL announcement, Disc shares declined 21.9%.

The players

Disc Medicine, Inc.

A biopharmaceutical company focused on developing therapies for rare and specialty disorders.

Levi & Korsinsky LLP

A nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.

Got photos? Submit your photos here. ›

What they’re saying

“Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) concerning potential violations of the federal securities laws.”

— Levi & Korsinsky

What’s next

The investigation will focus on whether Disc Medicine and its senior executives made statements to investors about the bitopertin program's regulatory prospects that did not fully reflect the risks and challenges the company was encountering in its interactions with the FDA prior to the CRL.

The takeaway

This case highlights the importance of transparency and accurate disclosure from biopharmaceutical companies, especially regarding the regulatory status of their lead drug candidates. Investors rely on these communications to make informed decisions, and any potential misrepresentations could have significant financial consequences.